Inhaled Ciprofloxacin as an Alternative Treatment for Infection with Coxiella burnetii
Inhaled liposomal ciprofloxacin demonstrated superior protection and reduced respiratory manifestations of Q fever compared to doxycycline and systemic ciprofloxacin. These findings suggest inhaled formulations may represent a viable alternative for the treatment of Q fever pneumonia. Further studies are needed to evaluate clinical applicability and long-term outcomes.
Authors
- Karleigh A. Hamblin
- Sarah V. Harding (ORCID: https://orcid.org/0000-0003-0159-5117)
- Francis Dayton
- Rachel E. Ireland (ORCID: https://orcid.org/0009-0009-3303-8367)
- Francisco J. Salguero (ORCID: https://orcid.org/0000-0002-5315-3882)
- Igor Gonda (ORCID: https://orcid.org/0000-0002-5206-794X)
- Stuart J. Armstrong (ORCID: https://orcid.org/0000-0002-5628-0481)
- Thomas R. Laws (ORCID: https://orcid.org/0000-0002-0142-9162)
- Isobel H. Norville (ORCID: https://orcid.org/0000-0003-3506-2466)
- Helen S. Atkins
- James Blanchard
- M. Gill Hartley
- Michelle Nelson
- Kevin R. Bewley
Institutions
- Defence Science and Technology Laboratory (GB)
- University of Leicester (GB)
- Aradigm (United States) (US)
- UK Health Security Agency (GB)
Publication Details
- Journal
- Antibiotics
- Published
- 2026-03-13
- DOI
- https://doi.org/10.3390/antibiotics15030293
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Grifols
- Defence Science and Technology Laboratory